Some patent battles are hard fought, as evidenced by Baxter's ($BAX) recent legal squabble with Fresenius Medical Care. In May, the U.S. Supreme Court declined to hear an appeal filed by Baxter, which sued Germany-based Fresenius in 2003 for allegedly infringing its patents on a kidney dialysis device. Baxter scored a victory in 2012, winning a $24 million judgment over Fresenius. But one year later, the U.S. Patent and Trademark Office canceled Baxter's patent, prompting a federal court to toss out the dispute.
Baxter appealed the decision, asking the nation's high court whether judges should defer to the Patent and Trademark Office during a patent dispute. Device heavyweights such as Medtronic ($MDT) encouraged the Supreme Court to hear the case, arguing that the current system prolongs court proceedings through dual-track litigation. But the company's complaints fell upon deaf ears, leaving the original ruling by the U.S. Court of Appeals for the Federal Circuit intact.
Supreme Court won't hear Baxter v. Fresenius patent case, irking industry
Fresenius beats back Baxter's patent suit